Report of the 17th Meeting of the STRATEGIC AND TECHNICAL ADVISORY GROUP FOR TUBERCULOSIS

12-14 June 2017

WHO Headquarters
Geneva, Switzerland
In its work on tuberculosis (TB), the World Health Organization (WHO) aims for a world free of TB and, as part of the Sustainable Development Goals, to end the global TB epidemic by 2030. It seeks to enable universal access to TB prevention and care, guide the global response to threats, and promote innovation. The WHO Secretariat, at all its levels, requires regular scientific, technical and strategic advice from its Strategic and Technical Advisory Group for Tuberculosis (STAG-TB).

**Mission and functions of the STAG-TB:**

The mission of the STAG-TB is to contribute to ending the TB epidemic, and eventually eliminating the disease, by providing state-of-the-art scientific and technical guidance to WHO. It has the following functions:
1.1 To provide to the Director-General independent evaluation of the strategic, scientific and technical aspects of WHO's Tuberculosis work;

1.2 To review, from a scientific and technical viewpoint, progress and challenges in WHO's TB-related core functions, including:
   1.2.1 The content, scope and dimension of WHO's development of TB policies, strategies and standards in TB prevention, care and control;
   1.2.2 The content, scope and dimension of WHO's collaboration, and support of, countries' efforts to control TB, including the provision of guidance and capacity-building on policies, strategies, standards and technical assistance;
   1.2.3 The content, scope and dimensions of WHO's TB epidemiological surveillance, monitoring, evaluation and operational research activities, their relevance to countries’ efforts to end the TB epidemic and approaches to be adopted;
   1.2.4 The content, scope and dimensions of WHO's promotion and support of partnerships, and of advocacy and communications for TB prevention, care and control worldwide;

1.3 To review and make recommendations on the establishment of committees, working groups, and other means through which scientific and technical matters are addressed; and

1.4 To advise on priorities between possible areas of WHO activities related to tuberculosis prevention, care and control.

The 17th meeting of the STAG-TB took place at WHO Headquarters on 12-14 June, 2017. The meeting was organized by the WHO Global TB Programme (GTB), which provides the Secretariat for the advisory body.

Dr Ibrahim Abubakar, Director of the Institute for Global Health of the University College London, was appointed by the WHO Director-General as STAG-TB Chair for the period of 2016-2018. He worked with the WHO Secretariat in the development of the 2017 meeting agenda. For 2017, there were twenty two members of STAG-TB with strong gender, geographical and expertise balance. Twenty-one members, including the Chair, were in attendance for the meeting.

The STAG-TB members were joined by over 175 technical, academic and civil society partners and WHO staff from Headquarters, all six Regional Offices and many WHO Country Offices.
This report provides a summary of the 17th meeting of STAG-TB, with a focus on the conclusions and recommendations provided by STAG-TB to WHO for each of the topics addressed. The meeting agenda is attached as Annex 1. Annex 2 provides the list of participants. The Terms of Reference for STAG-TB are provided at http://who.int/tb/advisory_bodies/stag/en/

Each STAG-TB meeting session began with an introductory presentation(s) by WHO staff and, in some cases, partners. Comments and suggested recommendations were provided by one or two STAG-TB members serving as session discussants, followed by comments and recommendations offered by other STAG-TB members, and additional comments by other participants.

The STAG-TB members serving as session discussants developed draft written recommendations, with the assistance of WHO rapporteurs. All draft recommendations were reviewed by STAG-TB members as a whole on the last day of the meeting, and any proposed revisions were recorded. The final revised recommendations were consolidated by the WHO Secretariat in this report with no further changes, except grammatical corrections and formatting. The consolidated report was reviewed by the STAG-TB Chair. The report was submitted via the Director, Global TB Programme to the Assistant Director-General, HIV/AIDS, TB, Malaria and Neglected Tropical Diseases Cluster, on behalf of the WHO Director-General.


Seventeenth meeting objectives:

At this 17th STAG-TB meeting in 2016, WHO requested STAG-TB to review and advise on a number of areas of WHO global TB work. The WHO STAG-TB Secretariat and the Chair of STAG-TB developed the agenda for the 17th meeting based on the suggested issues proposed by the STAG-TB members at their 16th meeting and on several new important priorities of the WHO Secretariat in 2017. The meeting was organized in two parts. The first part focused on issues recommended by STAG-TB and priority issues arising for evidence review and activity of WHO in TB during 2016-2017.

The second part focused on obtaining STAG-TB advice on the planning process, major outcome areas, draft policy briefs and declaration development process, for the first WHO Global Ministerial Conference on Ending TB in the Sustainable Development Era: A Multisectoral Response to be co-organized by WHO and the Ministry of Health of the
Russian Federation and hosted by the Russian Federation in Moscow, 16-17 November 2017.

Here are the specific agenda points covered following an introductory session:

**Part I:**
- Update on TB impact measurement
- Recent reviews of pharmacokinetics, pharmacodynamics and isoniazid-resistant TB: implications for WHO treatment policies
- Monitoring patient-centred care through health related quality of life metrics
- Updated on actions of the Civil Society Task Force on TB
- Expanding efforts to combat childhood TB
- Operational research to end TB at the country level

**Part II:**
- Introduction to conference aim, approach, outcome areas, policy package and declaration process
- Perspectives on ending TB and multisectoral action by UN agency partners
- Outcome area 1: Advancing TB response within UHC, AMR and SDG Agendas
- Outcome area 2: Increased and sustainable financing
- Outcome area 3: Scientific research and innovation
- Outcome area 4: Developing a multisectoral accountability framework

**SESSION 1: INTRODUCTION**

On behalf of the WHO Director-General, Dr Ren Minghui, Assistant Director-General, HIV/AIDS, TB, Malaria and Neglected Tropical Diseases Cluster, welcomed STAG-TB members and all other participants to the meeting. He noted the conclusion of Dr Margaret Chan’s two terms as WHO Director-General, and the election by the World Health Assembly of the new Director-General, Dr Tedros Adhanom Ghebreyesus and his planned term beginning in July, 2017.

Dr I. Abubakar, STAG-TB Chair, welcomed all members and introduced the provisional agenda for the meeting for adoption. D. Weil, WHO Global TB Programme Coordinator for Policy, Strategy & Innovations (PSI), and STAG-TB Secretariat lead, presented the Terms of Reference of STAG-TB, meeting processes and noted the review of meeting participant Declarations of Interest. No interests were deemed significant for the meeting, and no modification in participation was made to the meeting. Declared interests were recorded and are available from the Secretariat. The actions taken on
recommendations from the 2016 meeting were reported on as relevant to each session of the 2017 meeting.

An introductory video, done by M. Dias, WHO Global TB Programme was shown on the status of the TB epidemic, global response, and provided highlights of WHO’s TB-related products, consultations, and activities in the past year.

Dr Raviglione provided an overview presentation on “High-level action: driving momentum to End TB” on 2017 and 2018 high-level meetings addressing need to accelerate action to end TB and reach the End TB Strategy milestones and targets. He reflected on the latest WHO data, the opportunities with new transformational scientific innovations within and beyond TB, new WHO guidance, action across the sustainable development goals, and a new geopolitical environment.

WHO Regional advisers for TB from all of the WHO regions presented brief updates on their efforts to support countries in pursuing the End TB Strategy and regional plans of action related to the strategy, and aligned with wider regional strategies related to advancing universal health coverage and all health-related Sustainable Development Goals and addressing regional challenges, such as migration and complex emergencies. All presentations available from the WHO STAG-TB Secretariat at the Global TB Programme.

The STAG-TB Chair then introduced individual sessions for discussion, conclusions and recommendations (except where noted for information-only sessions).

**STAG-TB CONCLUSIONS AND RECOMMENDATIONS BY SESSION**

Presenter and STAG-TB Member discussant names for each session are shown in the meeting agenda (Annex 1).

**PART I**

**SESSION 2: TB IMPACT MEASUREMENT - 2016-2017 PROGRESS** - THIS WAS AN INFORMATION SESSION AND THE PRESENTATION PROVIDED IS AVAILABLE FROM THE WHO STAG-TB SECRETARIAT/GLOBAL TB PROGRAMME.
SESSION 3: COMPENDIUM OF WHO GUIDELINES AND ASSOCIATED STANDARDS: ENSURING OPTIMUM DELIVERY OF THE CASCADE OF CARE FOR PATIENTS WITH TUBERCULOSIS

STAG-TB:

- Acknowledges and applauds WHO in developing the comprehensive Compendium of policy guidelines and standards in a user-friendly layout that follows the cascade of care delivery for patients with TB incorporating website links to the detailed policy guidance.

- Recognizes that the proposed standards serve as a baseline for patient care for all countries irrespective of the conditionality of recommendations.

STAG-TB recommends that WHO:

1. Incorporate additional sections to address programmatic implementation and financing for the essential elements of the End TB Strategy, including addressing the needs of hard-to-reach populations.

2. Review existing guidelines and identify gaps where new policy guidance needs to be developed\(^1\).

3. Incorporate into the Compendium available guidance on the importance of social components of patient care, use of new drugs, adoption of public-private mix activities and International Standards of TB Care (ISTC), and TB/HIV monitoring and evaluation; and add an annex with a list of references for each standard.

4. Support civil society and partners to advocate with governments for implementation of the recommendations based on WHO tools, and to monitor implementation and country-level uptake.

5. In addition to civil society partners, involve academia and private practitioners in country-level implementation.

---

\(^1\) e.g. guidance for transitioning from microscopy to Xpert, as well as phasing out other old technologies, post-treatment patient care, treatment of non-MDR INH-resistant TB and incorporate into a subsequent version of the compendium.
6. Develop the Compendium as an electronic tool or App, translated into the six WHO official languages, and one that can be updated at least annually while ensuring consistency in the policy recommendations throughout the document with accurate website links.

SESSION 4: RECENT REVIEWS OF PHARMACOKINETICS, PHARMACODYNAMICS AND ISONIAZID-RESISTANT TB: IMPLICATIONS FOR WHO TREATMENT POLICIES

STAG-TB commends WHO for the major effort undertaken to:

- Address the key clinical questions arising from the 2016 policies and updates on the management of MDR-TB;
- Explore the newly emerging data from molecular diagnostics and pharmacokinetics/pharmacodynamics (PK/PD) of TB medicines;
- Revise critical concentrations for phenotypic drug susceptibility testing; and
- Develop policy guidance on treatment of isoniazid-resistant TB based on the latest scientific evidence.

STAG-TB acknowledges:

- The importance of growing knowledge and emerging data from PK/PD studies and from molecular diagnostic innovations in helping to optimise treatments success, and reduce the development of resistance and drug adverse effects; As such, PK/PD data complements the MDR-TB treatment guidance from clinical studies which informed the 2016 WHO policy recommendations;
- The importance of exploring the optimum dosing of rifampicin for treatment of rifampicin-susceptible TB and linking PK/PD data to the results of ongoing clinical trials on high-dose rifampicin; In doing so, other rifamycins (eg. rifapentine for preventive therapy) also should be investigated;
- That emerging innovations and new data may imply future individualisation of MDR-TB treatment at country and patient level, in order to improve treatment outcomes, reduce the development of additional resistance and better balance effectiveness with patient safety;
- The need to accelerate the development of molecular drug-susceptibility testing (DST) technologies, particularly the rapid, near-point-of-care test for isoniazid resistance as a means to treat this form of TB more fast and appropriately, and to optimise access to existing molecular capacity at country level (eg. the GeneXpert
platform as well as sequencing capability already existing for diseases other than TB);  
- The need for more data on PK/PD and molecular DST that could help optimise patient care.

STAG-TB recommends that WHO:

1. As immediate priorities, revise and update treatment guidance focusing on: (i) the inclusion of fluoroquinolones in treatment of isoniazid-resistant TB; (ii) limiting injectable agents to situations in which they cannot be avoided; (iii) adequate regimens for retreatment cases without an HR isoniazid-resistant-TB diagnosis which protects them from acquiring additional resistance (given the discontinuation of the “category 2” regimen); and, (iv) the further review of the dosages of rifamycins.

2. As mid-term priorities, assess the evidence for molecular diagnosis (including targeted or whole genome sequencing) as the future reference standard for drug-resistant TB diagnosis and clinical decision-making, and for developing a standardised approach to precision medicine that can be implemented regardless of the resource-setting.

SESSION 5: MONITORING PATIENT-CENTRED CARE THROUGH HEALTH-RELATED QUALITY OF LIFE METRICS

STAG-TB acknowledges that:

- Current approaches to TB care still rely heavily upon biomedical interventions and often miss out on other care aspects which require a broader educational, psychological, and social undertaking;
- Ignoring quality of life is unacceptable and unethical, and stigmatization can delay health-seeking behaviour and influence adversely treatment completion;
- The metrics associated with TB-related quality of life may require further development. The case of measurement of TB patient and household costs shows that new metrics can be developed within a relatively short time.

STAG-TB recommends that WHO:

1. Pursue the way forward presented for assessment/measurement of TB health-related quality of life (QOL), strengthening the process and exploring the possible
linkages/methods to capture data linked to TB patient-household cost (as well as other dimensions of patient QOL), addressing current limitations in the methodologies, and engaging affected communities and civil society in the process.

2. Pursue a holistic approach to care (including rehabilitation services and post-treatment care and due attention to the roles of different health workers, e.g., nurses vs. doctors), building on the recently-developed WHO policies relevant for patient-centred care and on well-known and feasible approaches to patient care, to improve outcomes beyond the well-defined treatment outcomes.

3. Clarify and further develop its work in this area.

4. Explore existing collaborative frameworks between TB programmes and mental health care services (as well as other components of NCDs, e.g. tobacco-related disease, nutrition) as part of a TB patient-centred care response, mental health being one key dimension of health related quality of life affected in people with TB which may be better dealt with through integration of services, similar to TB/HIV collaboration.

5. Promote research on currently neglected areas related with TB health related quality of life, e.g. TB stigma, mental health, and disability).

SESSION 6: UPDATE ON ACTIONS OF THE CIVIL SOCIETY TASK FORCE ON TB - THIS WAS AN INFORMATION SESSION AND THE PRESENTATION PROVIDED IS AVAILABLE FROM THE WHO STAG-TB SECRETARIAT/GLOBAL TB PROGRAMME.

SESSION 7: EXPANDING EFFORTS TO COMBAT CHILDHOOD TB

STAG-TB recognizes and acknowledges:

- The progress made by WHO and partners since the launch of the Childhood TB Roadmap in 2013;
- That childhood TB is increasingly included in national TB strategic plans and other relevant documents;
- The availability and country uptake of the new child-friendly fixed dose combinations for treatment of susceptible TB;
• The encouraging examples from pilot projects of decentralized capacity for prevention, diagnosis and treatment of childhood TB, including household-based contact screening;
• The opportunities for better linkages with existing platforms for maternal and child health at the frontline care level;

STAG-TB recognizes the following major gaps:

• Although the use of TB preventive therapy in young (<5 years of age) children with household exposure to TB is included in most national strategic plans, this is rarely (if ever) implemented;
• TB is a common (but often unrecognized) cause of death in young children in TB endemic areas, and most children with TB are incorrectly diagnosed, while diagnostic approaches remain highly centralized;
• Children treated in referral hospitals or in the private sector are rarely included in figures reported to the WHO;
• Disaggregation of the adolescent age group is currently impossible due to TB age brackets and reporting frameworks used (paper-based);
• The Childhood TB Roadmap published in 2013 did not include clear targets and timelines and failed address the needs of adolescents.

STAG-TB recommends that WHO:

1. Strongly promote programmatic scale-up of household contact screening to identify children with TB disease, and those children with TB infection who benefit most from preventive therapy.

2. Review ongoing trials and upcoming evidence on the use of non-sputum based samples (e.g. nasopharyngeal aspirate (NPA), stool).

3. Evaluate existing models of decentralized care for children with TB and develop targeted training and management tools [algorithms, Standards of Practice (SOPs)] that would facilitate integrated service delivery.

4. Support National TB Programmes (NTPs) in establishing strong linkages across the health sector and with the private sector in order to better capture children diagnosed and treated outside of NTPs and to improve treatment (e.g. using existing
tools such as the IMCI; PPM framework) & recommends WHO to continue to engage with UNICEF, other UN agencies and partners.

5. Include in WHO Global TB Report data on adolescent TB (age range 10-19yrs), initially from countries with case-based electronic surveillance systems, with the aim of estimating the disease burden and developing programmatic guidance.

6. Update the 2013 Childhood TB Roadmap with renewed targets and timelines and broaden its scope to include adolescents.

SESSION 8: OPERATIONALIZING RESEARCH TO END TB AT THE COUNTRY LEVEL

STAG-TB:

- Welcomes the activities undertaken by GTB to promote research at country level through the development of national TB research networks and plans, and encourages their wider adoption to assist countries in their efforts to End TB.

STAG-TB recommends that WHO:

1. Reinforces its work with low- and medium-income, high TB burden countries to provide support in research planning and implementation, and assist in the development of research platforms (regional or thematic) to enhance collaborations, leverage funding, and facilitate knowledge sharing and capacity building.

2. Support countries to develop implementation work plans stemming from national research agendas, including relevant country specific indicators to reflect adherence to workplans.

3. In collaboration with governments, funders and other relevant stakeholders, facilitate the development and implementation of innovative research financing and capacity building strategies at the global and country level.

PART II

REVIEW OF POLICY CONTENT OF THE FIRST WHO GLOBAL MINISTERIAL CONFERENCE ON ENDING TB IN THE SUSTAINABLE DEVELOPMENT ERA: A MULTIktor RESPONSE"
Dr M. Raviglione and Dr T. Kasaeva, STAG-TB Member and Ministry of Health of the Russian Federation presented an overview of the aims, objectives, and planning process for the WHO Global Ministerial Conference co-organized with the Russian Federation and to be held in Moscow on November 16 and 17, 2017. Full materials are available on the WHO Conference website. STAG-TB and all participants were asked to provide their advice and feedback on the aims, objectives, organization of the conference and proposed invitees. Day 2 the STAG-TB Meeting was dedicated to in-depth discussion on each of the key outcome areas and sub-thematic tracks of the Conference, and the drafts of the related policy briefs developed to inform the Conference. STAG-TB recommendations on process and content are noted below.

As the Conference aims to address multisectoral action needed to end the epidemic, within the context of the UN Sustainable Development Agenda, WHO invited representatives of several UN agencies who are directly working to fight TB within the remit of their agencies to comment on the Conference. The speakers all were committed to the aims and objectives of the Conference for action at country level and its contribution in moving towards the UNGA High-Level Meeting (HLM) on TB in 2018. A. Maina of the UN High Commission on Refugees working on the health of refugees, including addressing prevention and care of TB among their priorities. P. Dhavan of the International Organization for Migration working on the health of migrants, with significant efforts specifically in support of TB prevention and care of migrants, and both spoke also to cross-UN efforts to address the migrant and refugee crisis. A. Detjen of UNICEF spoke to the special efforts needed to address TB among the development concerns of children and collaborative efforts with WHO and many partners to improve TB treatment and care for children. A. Reid, coordinating TB/HIV efforts of UNAIDS spoke to the new momentum that is possible for accelerating and scaling up joint actions against the two epidemics, and the lessons learned from HIV from such high-level political discussions possible through the Ministerial Conference and the UNGA HLM.

**OUTCOME AREA 1: ADVANCING THE TB RESPONSE WITHIN THE UNIVERSAL HEALTH COVERAGE, AMR AND SDG AGENDAS**

**STAG-TB:**

- Commends the WHO Global TB Programme for the development of the draft policy briefs on outcome area 1 and its related thematic tracks;
• Acknowledges the extent of technical input and consultation that has been undertaken with countries, civil society and partners in the development of these draft briefing documents;
• Recognizes that these briefs will serve as background documents for the sessions focused on this outcome area and thematic tracks, and that these drafts will subsequently be strengthened for clarity and content;
• Supports the process for development of the declaration (and its overall preamble).

**STAG-TB recommends that WHO:**

Incorporate the following inputs to strengthen the Ministerial Conference policy briefs on outcome area 1 and its related thematic tracks:

1. To provide political leadership and commitment, the recommended Commission should be convened by the Head of State who should remain its patron with multisectoral membership and potentially chaired by the health minister (develop a plan).

2. Countries should fast track universal access to health care through all state and non-state care providers to reach all people with TB including the missing cases, (human resources) especially those managed by the private sector, ensuring no one is left behind.

3. The proposed End TB charter for ethics, equity and human rights, should be supported by a legislative framework, and developed with clarity of language, process and inclusive of male gender (burden and missing cases), vulnerable groups and poverty related issues.

4. Measures to improve prevention including prompt identification and treatment of tuberculosis, should be reflected in the brief for all areas inclusive of MDR-TB.

**OUTCOME AREA 2: INCREASED AND SUSTAINABLE FINANCING**

**STAG-TB:**

Supports fully the aim of Outcome Area 2 for the Ministerial Conference, with a focus on driving commitments for domestic and global financing for UHC, TB-specific needs, and to eliminate catastrophic costs for TB patients and affected households.
STAG-TB recommends that WHO:

In revising the policy brief, declaration content and in preparing for the Conference and UNGA HLM:

1. Reinforce the top messages that: TB investment represents great value for money, that underfinancing of TB response is a threat, and ensuring allocative efficiency and quality are important;
2. Work with relevant experts to: (a) formulate an improved indicator(s) to measure domestic TB financing commitment relative to full needs; and (b) estimate the economic risks of failure to invest now;
3. In keeping with the policy brief, (a) Support country-led work to develop and promote cogent, persuasive, and attractive End TB investment cases, involve partners with financing, economics, and communications capacity, align work with National Strategic Plans, and pursue innovative financing streams such as with the private sector; and (b) Coordinate key partners to support the actions required at country level to achieve the financing targets.

OUTCOME AREA 3: SCIENTIFIC RESEARCH AND INNOVATION

STAG-TB:

- Welcomes the development of a background policy paper on Global TB R&D Investments 2005–2016: Past, Present, Future in preparation for the Global Ministerial Conference in Moscow November 2017 and the policy brief aligning asks to promote and expand TB research and innovation both at the national and international levels;
- Supports the proposition of development of a Global Coalition for TB Research as a way to promote research, broaden funding sources and optimize research investments based on international consensus and support global efforts to invigorate TB research.

STAG-TB recommends that WHO:

1. Strongly advocate the need to conduct research along the full spectrum, ensure that basic and translational research for development of new tools be linked
with implementation research on the use and scale-up of current and new tools and highlight the need to conduct multi-disciplinary and multisectoral research.

2. Invite Ministries of Science and Technology (MoST) - or equivalent - along with representatives of Ministries of Health at the Conference, engage MoST in discussions about TB R&D funding commitments, and involve representatives of the private sector to collectively raise funds and develop efficient information-sharing and capacity-building pathways.

3. Strongly promote, together with relevant stakeholders, the development of a Global Coalition for TB Research that addresses new funding mechanism(s), with a view to promote and support TB R&D within the context of SDGs, as well as existing or forthcoming initiatives - such as the AMR initiative - and including engagement from the BRICS (Brazil, Russia, India, China and South Africa).

SESSION 4: DEVELOPING AN END TB MULTISECTORAL ACCOUNTABILITY FRAMEWORK

STAG-TB:
• Recognizes the value of a multisectoral accountability framework for TB that builds on existing global and national processes for monitoring, review and action.
• Acknowledges the presented content and recognizes the need to update the related content in the draft policy brief.

STAG-TB recommends that WHO:

1. Lead the development of a multisectoral accountability framework, working with senior officials in Ministries of Health, civil society, other UN agencies and partners, as a key component of preparations for, and deliverable of, the UN high-level meeting on TB in 2018.

2. Expand the scope of the annual WHO global TB report, in particular to include monitoring of new indicators that are part of the accountability framework.
   • This is expected to include the 14 SDG indicators that are associated with TB incidence, and new indicators (and related targets) that will be needed to track commitments and calls to action in the Declaration adopted at the 2017 WHO Ministerial Conference.

ADDED ITEM: THE WHO PRIORITY PATHOGENS LIST
The Chair of the STAG-TB called for STAG-TB discussion of the WHO Priority Pathogens List, and ongoing work on related final analysis and a report, as an additional agenda item.²

STAG-TB:

- Acknowledges that TB is the leading pathogen causing deaths in the world and the efforts of WHO to revisit the priority pathogen list and explore criteria and methods with a view to re-examine whether *Mycobacterium tuberculosis* may be included in the list.

- Understanding that indicators used in the application of the criteria are inadequate to allow inclusion of *M. tuberculosis*, strongly recommends that WHO withdraw the current list, and that it pursue immediate review of the application of the criteria for selection of pathogens to take into account the limitations of the original prioritization process.

- Supports, following the revision of the criteria, the production of a revised list and the appropriate placement of *M. tuberculosis* on such a list.

**PLANNING OF THE 2018 STAG-TB MEETING**

The WHO Secretariat announced the planned dates for the 18th annual STAG-TB meeting: **11-13 June 2018** at WHO Headquarters in Geneva. Proposed agenda items for the 2018 session will be discussed with STAG-TB members in advance.

**CLOSING**

The meeting was closed with final remarks and appreciation to all participants offered by Dr Ren Minghui and Dr Raviglione on behalf of the World Health Organization, and by Dr Abubakar on behalf of the Strategic and Technical Advisory Group for Tuberculosis. Dr Abubakar acknowledged the outstanding achievements of Dr Raviglione as Director of the WHO Global TB Programme since 2003, as this STAG-TB meeting was likely to be the last STAG-TB meeting before Dr Raviglione’s retirement. The meeting’s participants

² Note: Subsequent to the STAG-TB 2017 meeting, and with awareness of the recommendations of STAG-TB and the concerns raised by other partners, WHO pursued collaborative work across the Department of Essential Medicines and Health Products and the Global TB Programme towards an updated expanded analysis and a final report on prioritization of pathogens for discovery, research and development of new antibiotics for drug-resistant bacterial infections and tuberculosis, published in September, 2017.
gave Dr Raviglione a standing ovation, and Dr Raviglione appreciated the contributions made by STAG-TB members to the work of WHO since the establishment of STAG-TB in 2001.
### MONDAY, 12 JUNE 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00– 10:30</td>
<td><strong>SESSION 1: Opening and overview</strong></td>
</tr>
<tr>
<td></td>
<td>Welcome and introductions</td>
</tr>
<tr>
<td></td>
<td>a. Objectives, agenda and follow-up on STAG-TB 2016 recommendations</td>
</tr>
<tr>
<td></td>
<td>b. Opening video</td>
</tr>
<tr>
<td></td>
<td>c. High level action: Driving momentum to end TB</td>
</tr>
<tr>
<td></td>
<td>d. Progress reports from Regions</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>10:30– 10:50</td>
<td>Coffee</td>
</tr>
<tr>
<td>10:50– 11:30</td>
<td><strong>SESSION 2: TB impact measurement: 2016-2017 progress</strong> (information session)</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>11:30– 12:30</td>
<td><strong>SESSION 3: Compendium of WHO guidelines and</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Session Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>12:30– 13:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:30– 14:30</td>
<td><strong>SESSION 4: Recent reviews of pharmacokinetics, pharmacodynamics and isoniazid-resistant TB: implications for WHO treatment policies</strong></td>
</tr>
<tr>
<td></td>
<td>Discussant</td>
</tr>
<tr>
<td>14:30– 15:30</td>
<td><strong>SESSION 5: Monitoring patient-centred care through health-related quality of life metrics</strong></td>
</tr>
<tr>
<td></td>
<td>Discussant</td>
</tr>
<tr>
<td>15:30– 15:50</td>
<td>Coffee</td>
</tr>
<tr>
<td>15:50-16:20</td>
<td><strong>SESSION 6: Update on actions of the Civil Society Task Force on TB</strong></td>
</tr>
<tr>
<td>16:20 -17:20</td>
<td><strong>SESSION 7: Expanding efforts to combat childhood TB</strong></td>
</tr>
<tr>
<td></td>
<td>Discussant</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>17:20– 18.20</td>
<td><strong>SESSION 8: Operationalizing research to end TB at the country level</strong></td>
</tr>
<tr>
<td></td>
<td>Discussant</td>
</tr>
<tr>
<td></td>
<td>Discussion and STAG recommendations</td>
</tr>
<tr>
<td>18:20– 18:30</td>
<td><strong>Summary of the day</strong></td>
</tr>
<tr>
<td></td>
<td>I. Abubakar, Chair</td>
</tr>
<tr>
<td>18:30– 20:00</td>
<td><strong>RECEPTION - UNAIDS/WHO D Building Cafe</strong></td>
</tr>
</tbody>
</table>

**TUESDAY, 13 JUNE 2017**


<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 – 10:00</td>
<td><strong>Introduction:</strong> Conference aim, approach, key outcome areas, declaration process and roadmap 2017-2018</td>
</tr>
<tr>
<td></td>
<td>Short comments from UN agency partners on multisectoral action</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td></td>
<td>Conference policy package and introduction to the sessions</td>
</tr>
<tr>
<td>10:00 – 10:20</td>
<td><strong>Coffee</strong></td>
</tr>
</tbody>
</table>

**Session 1:** Universal health coverage, social protection and addressing the TB determinants

<table>
<thead>
<tr>
<th>Time</th>
<th>Panel:</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15 – 12:30</td>
<td><strong>Overview for the thematic area</strong></td>
</tr>
<tr>
<td></td>
<td>a. Respect for equity, ethics and human rights</td>
</tr>
<tr>
<td></td>
<td>b. Action on AMR, health security and MDR-TB</td>
</tr>
<tr>
<td></td>
<td>M. Uplekar</td>
</tr>
<tr>
<td></td>
<td>M. Dias</td>
</tr>
<tr>
<td></td>
<td>K. Weyer</td>
</tr>
</tbody>
</table>
c. Stepped up TB/HIV response
d. Synergies across the responses to TB and non-communicable diseases

Discussant

Discussion and STAG-TB recommendations

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Discussant</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 – 13:30</td>
<td>Lunch</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>13:30 – 14:30</td>
<td>Session 2: Increased and sustainable financing</td>
<td>Overview of the thematic area</td>
<td>D. Weil</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussant</td>
<td>C. Vincent</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion and STAG-TB recommendations</td>
<td></td>
</tr>
<tr>
<td>14:30 – 15:30</td>
<td>Session 3: Scientific research and innovation</td>
<td>Overview of the thematic area</td>
<td>C. Lienhardt</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Background analysis on trends in TB research financing</td>
<td>E. Lessem</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussant</td>
<td>N.V. Nhung</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion and STAG-TB recommendations</td>
<td></td>
</tr>
<tr>
<td>15:30 – 15:50</td>
<td>Coffee</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>15:50 – 16:50</td>
<td>Session 4: Multisectoral accountability framework</td>
<td>Developing an End TB multisectoral accountability framework</td>
<td>K. Floyd</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussant</td>
<td>T. Lwin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion and STAG-TB recommendations</td>
<td></td>
</tr>
</tbody>
</table>

Day 2 Wrap-up
16:50 - 17:00 | Summary of the discussions and wrap-up | I. Abubakar

**WEDNESDAY, 14 JUNE 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair/Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 10:30</td>
<td>STAG-TB recommendations review</td>
<td>Chair STAG Members</td>
</tr>
<tr>
<td>10:30 -10:50</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>10:50 – 12:30</td>
<td>STAG-TB recommendations review</td>
<td></td>
</tr>
<tr>
<td>12:30 – 12:45</td>
<td>18th STAG-TB Meeting, 11-13 June 2018</td>
<td>STAG-TB Members</td>
</tr>
<tr>
<td></td>
<td>STAG-TB suggestions for the agenda</td>
<td></td>
</tr>
<tr>
<td>12:45 – 13:00</td>
<td>CLOSING REMARKS</td>
<td>I. Abubakar Ren Minghui M. Raviglione</td>
</tr>
</tbody>
</table>
**STAG-TB Members 2017**

1. **Prof. Ibrahim Abubakar**  
   Chair, STAG-TB  
   Director, Institute for Global Health  
   University College London  
   London  
   United Kingdom

2. **Dr Farhana Amanullah**  
   Department of Pediatrics  
   The Indus Hospital and  
   Aga Khan  
   University Hospital  
   Karachi  
   Pakistan

3. **Dr Catharina Boehme**  
   Chief Executive Officer  
   Foundation for Innovative New  
   Diagnostics (FIND)  
   Geneva  
   Switzerland

4. **Dr Daniel Chin**  
   Deputy Director for Delivery  
   TB Program  
   Global Health Program  
   Bill & Melinda Gates Foundation  
   Seattle, WA  
   USA

5. **Dr Manfred Danilovits**  
   NTP Coordinator and Head of  
   Department of Tuberculosis  
   Tartu University - Lung Clinic  
   Tartu  
   Estonia

6. **Dr Betina Durovni**  
   Professor  
   University of Rio de Janeiro  
   Rio de Janeiro  
   Brazil

7. **Dr Unyeong Go**  
   Director, Center for Disease  
   Prevention and Korean Network for  
   Organ Sharing  
   Korea Centers for Disease Control  
   and Prevention  
   Seoul  
   Republic of Korea

8. **Dr Christy Hanson**  
   Senior Programme Officer  
   TB Programme  
   Global Health Programme  
   Bill & Melinda Gates Foundation  
   Seattle, WA  
   USA

9. **Dr Tereza C. Kasaeva**  
   Deputy Director  
   Department of Healthcare and  
   Sanatorium-Resort Engagement  
   Ministry of Health  
   Moscow  
   Russian Federation

10. **Dr Sunil Khaparde**  
    National TB Programme Manager  
    Central TB Division  
    Ministry of Health and Family  
    Welfare  
    Government of India  
    New Delhi  
    India

11. **Ms Erica Lessem**  
    TB/HIV Director  
    Treatment Action Group  
    New York, NY  
    United States

12. **Dr Thandar Lwin**  
    Director  
    Disease Control  
    Department of Public Health  
    Ministry of Health  
    Nay Pyi Taw  
    Myanmar

13. **Dr Thato Mosidi**
Public Health Medicine Registrar
Western Cape
Department of Health
Cape Town
South Africa

14. Dr Beatrice Mutayoba
Programme Manager
National Tuberculosis and Leprosy
Programme
Ministry of Health and Social
Welfare
Dar es Salaam
United Republic of Tanzania

15. Dr Mahshid Nasehi
National TB Programme Manager
Ministry of Health and Medical
Education
Tehran
Islamic Republic of Iran

16. Dr Nguyen Viet Nhung
Director, National Lung Hospital
Manager of the National
Tuberculosis Control Program
Hanoi
Viet Nam

17. Professor Bertie Squire
Professor of Clinical Tropical
Medicine
Liverpool School of Tropical
Medicine
Liverpool
United Kingdom

18. Dr Kitty van Weezenbeek
Executive Director
KNCV Tuberculosis Foundation
The Hague
The Netherlands

19. Dr Anna Vassall
Reader in Health Economics
London School of Hygiene &
Tropical Medicine
London
United Kingdom

20. Ms Cheri Vincent
Chief, Infectious Diseases Division
Bureau of Global Health
US Agency for International
Development
Washington, DC
USA

21. Dr Rony Zachariah
Director
Operational Research & Strategic
Advisor to the Director General
Médecins Sans Frontières
Brussels Operational Center
(LuxOR)
Luxembourg

Temporary Advisers

22. Dr Heather Alexander
Chair, Global Laboratory Initiative
Task Force (GLI)
Tuberculosis and Opportunistic
Infections Unit Lead
US Centers for Disease Control and
Prevention
Atlanta, Georgia
USA

23. Dr Jaap Broekmans
Chair, WHO Global Task Force on
TB Impact Measurement
The Hague
The Netherlands

24. Dr Muhwa Jeremiah Chakaya
Chief Research Officer
Centre for Respiratory Diseases
Research
Kenya Medical Research Institute
Nairobi
Kenya

25. Dr Charles Daley
Chair, Global Drug-resistant TB Initiative (GDI)
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver
USA

WHO Civil Society Task Force on TB Members

26. Ms Jamila Ismoilova
27. Ms Timpiyian Leseni
28. Mr Olayesi Babatunde Oyebisi
29. Ms Gracia Violeta Ross Quiroga
30. Mr Sameer Sah
31. Ms Mandy Slutsker
32. Mr Ademe Tsegaye

Other Participants

33. Dr Sevim Ahmedov
Senior TB Technical Advisor
USAID
Washington, DC
USA

34. Dr RV Asokan
RNTCP National Coordinator
IMA
Deen Hospital
Indian Medical Association
Kerala
India

35. Dr Leopold Blanc
Consultant, TB and health systems
Prévessin
France

36. Dr Amy Bloom
Senior Technical Advisor
Bureau of Global Health
US Agency for International Development
Washington, DC
USA

37. Dr Draurio Barreira
Technical Manager
UNITAID
Geneva
Switzerland

38. Dr Delia Boccia
London School of Hygiene and Tropical Medicine
London
UK

39. Dr Grania Brigden
Director, 3P’s Project
The Union

40. Dr Karen Brudney
Senior Adviser to CDC on TB
Centers for Disease Control and Prevention
Atlanta, GA
USA

41. Dr Kenneth Castro
Senior TB Technical Advisor/USAID & Professor/Emory University
Atlanta
USA

42. Dr Gavin Churchyard
Chief Executive Officer
The Aurum Institute
Parktown
Johannesburg
South Africa
43. **Ms Monica Chaler**  
Program Manager  
Eli Lilly & Company  
Madrid  
Spain

44. **Isaac Chikwanha**  
Access Campaign  
Médecins Sans Frontières (MSF)  
Geneva

45. **Dr Daniela Cirillo**  
Head, Emerging Bacterial Pathogens  
Unit  
San Raffaele del Monte Tabor Foundation  
San Raffaele Scientific Institute  
Milan  
Italy

46. **Dr Bill Coggin**  
Senior Technical Officer  
Div of Global HIV and TB  
CDC Atlanta  
USA

47. **Dr Vivian Cox**  
Chair, DR-TB Stat Task Force, GDI  
GDI Observer  
Chattanooga, TN  
USA

48. **Ms Jane Coyne**  
UCSF  
San Francisco  
USA

49. **Dr Jacob Creswell**  
Team Leader - Innovations & Grants  
Stop TB Partnership  
Geneva  
Switzerland

50. **Dr Anand Date**  
Associate Branch Chief  
Centres for Disease Control & Prevention  
Atlanta, GA  
USA

51. **Ms Stephanie Denamps**  
Country Support Manager  
Clinton Health Access Initiative  
London  
United Kingdom

52. **Dr Claudia Denkinger**  
Head of TB Programme  
Foundation for Innovative New Diagnostics (FIND)  
Geneva  
Switzerland

53. **Dr Anna Detjen**  
Health Specialist, Childhood TB  
UNICEF  
New York, NY  
USA

54. **Dr Poonam Dhavan**  
Migration Health Programme Coordinator  
International Organization for Migration  
Geneva  
Switzerland

55. **Ms Fran Du Melle**  
Sr. Director  
International Programmes & Activities Organisation  
American Thoracic Society  
New York  
USA

56. **Dr Paula Fujiwara**  
Scientific Director  
International Union Against Tuberculosis and Lung Disease (The Union)
57. Dr Alexander Golubkov
Senior TB Technical Advisor
US Agency for International Development (USAID)
Washington, D.C.
USA

58. Dr Philip Hopewell
Professor of Medicine
Curry International TB Center
University of California
San Francisco General Hospital
San Francisco, CA
USA

59. Dr Akramul Islam
Director, Tuberculosis and Malaria Control
Water, Sanitation & Hygiene
Bangladesh Rural Advancement Committee (BRAC)
Dhaka
Bangladesh

60. Mr Paul Jensen
Director of Policy and Strategy
The Union
Paris
France

61. Professor Afranio Kritski
Medical School
Federal University of Rio de Janeiro
Rio de Janeiro
Brazil

62. Dr Evan Lee
Vice President
Global Health Programs & Access
Eli Lilly
Geneva
Switzerland

63. Dr Ethel Maciel
Professor
Universidade Federal do Espirito Santo
Vitória
Brazil

64. Mr Allen Gidraf Kahindo Maina
UNHCR
Geneva
Switzerland

65. Dr Shelly Malhotra
Director, Market Access
TB Alliance
New York, NY
USA

66. Dr Susan Maloney
Chief, Global TB Branch
Center for Global Health Centers for Disease Control and Prevention
Atlanta, GA
USA

67. Ms Joanne Manrique
President
Center for Global Health and Diplomacy
Washington DC
USA

68. Prof Ben Marais
Deputy Director
Marie Bashir Institute for Infectious Diseases and Biosecurity (MBI)
Centre for Research Excellence in Tuberculosis (TB-CRE)
Infectious Diseases Clinician
The Children’s Hospital at Westmead
University of Sydney
Sydney
Australia
69. Dr Refiloe Matji  
Regional Director  
University Research Corporation  
Pretoria  
South Africa

70. Dr Alberto Matteelli  
Associate Professor  
University of Brescia  
Brescia  
Italy

71. Mr Jean-Jacques Monot

72. Dr Ya Diul Mukadi  
Senior Technical Adviser  
Global Health Bureau  
US Agency for International Development  
Washington, DC  
USA

73. Dr Yamuna Mundade  
UNITAID

74. Dr Gidado Mustapha  
Challenge TB  
The Hague  
The Netherlands

75. Ms Eva Nathanson  
Program Manager TB  
UNITAID  
Geneva Switzerland

76. Dr Pierre-Yves Norval  
Consultant  
France

77. Dr Temitayo Odusote  
USAID Nigeria  
Abuja  
Nigeria

78. Dr Cha Jeong Ok

79. Dr Kosuke Okada  
Director  
International Programmes  
Japan Anti-Tuberculosis Association  
Tokyo  
Japan

80. Dr Lee Reichman  
Global TB Institute  
New Jersey Medical School at Rutgers the State University  
Newark, NJ  
USA

81. Dr Alasdair Reid  
Senior Adviser  
UNAIDS  
Geneva  
Switzerland

82. Dr Sarita Shah  
US Centers for Disease Control and Prevention  
Atlanta, GA  
USA

83. Dr Suvanand Sahu  
Deputy Executive Secretary  
Stop TB Partnership  
Geneva  
Switzerland

84. Dr Lal Sadasivan Sreemathy  
TB Technical Director  
PATH  
Washington, DC
85. **Dr Karam Shah**  
Advisor to the Ministry of Health Services Regulation & Coordination (MHSR&C)  
Advisor to the Stop TB Pakistan  
Islamabad  
Pakistan

86. **Dr Mariam Sianozova**  
Regional Director for Europe and Eurasia  
Project HOPE  
Yerevan  
Armenia

87. **Dr Kassim Sidibe**  
Medical Epidemiologist  
Global Tuberculosis Branch  
Division  
Centers for Disease Control and Prevention  
Atlanta, GA  
USA

88. **Dr Lisa Stevens**  
Senior Technical Advisor, TB and HIV  
FHI 360  
Bangkok  
Thailand

89. **Ezio Tavora Dos Santos Filho**  
Rede TB  
Brazil

90. **Dr Zelalem (Zami) Temesgen**  
Professor of Medicine  
Executive Director  
Mayo Clinic Center for Tuberculosis  
Rochester, MN  
USA

91. **Dr Ademe Tsegaye Adgo**  
Program Coordinator  
Doctors with Africa CUAMM  
Ethiopia

92. **Dr Ersin Topcuoglu**  
Deputy Director TB CARE I Program  
KNCV Tuberculosis Foundation  
The Hague  
The Netherlands

93. **Dr Carrie Tudor**  
TB Project Director  
International Council of Nurses  
Pretoria  
South Africa

94. **Mrs Garance Fannie Upham**  
Vice-President, ACdeBMR  
World Alliance Against Antibiotic Resistance (WAAAR)  
Ferney-Voltaire  
France

95. **Prof Irina Vasilyeva**  
Chief TB Specialist  
Moscow  
Russian Federation

96. **Dr Marieke van der Werf**  
Head of Disease Programme, TB  
ECDC  
Stockholm  
Sweden

97. **Dr Eliud Wandwalo**  
Senior Technical Advisor  
Tuberculosis  
The Global Fund to Fight AIDS, Tuberculosis and Malaria  
Geneva  
Switzerland
98. Dr William Wells  
Senior TB Technical Advisor  
US Agency for International Development  
Washington DC  
USA

99. Jason Wright  
Management Science for Health  
(MSH)  
Virginia  
USA

100. Dr Norio Yamada  
RIT, JATA  
Japan

101. Dr Mohammed Yassin  
Senior Advisor, Tuberculosis  
The Global Fund to Fight AIDS, Tuberculosis and Malaria  
Geneva  
Switzerland

102. Dr Andrei Zagorski  
Country Operations Manager  
Global Drug Facility Team  
Stop TB Partnership  
Geneva  
Switzerland

WHO Staff  
(Regional/Country Offices)

AFRO
103. Dr Daniel Kibuga,  
TB Programme Manager  
AFRO
104. Dr Dinnuy Kombate-Noudjo,  
IST/CA
105. Dr Wilfred Nkhoma, IST/ESA
106. Dr Andre Ndongosieme,  
ISW/WA
107. Dr Javier Aramburu, WHO  
Angola

108. Dr Richard Banda,  
WHO/Tanzania
109. Dr Nicolas Nkiere, WHO DRC
110. Dr Kassa Hailu Ketema, WHO  
Ethiopia
111. Dr Eva de Carvalho, WHO  
Mozambique
112. Dr Ayodele Awe, WHO Nigeria
113. Dr Cornelia Hennig, WHO  
Sierra Leone
114. Dr Nkateko Mkhondo, WHO  
South Africa
115. Dr Lastone Chitembo, WHO  
Zambia
116. Dr Patrick Hazangwe, WHO  
Zimbabwe

AMRO
117. Dr Rafael Lopez-Olarue,  
TB officer AMRO

EMRO
118. Dr Mohamed Abdel Aziz, TB  
Regional Adviser
119. Dr Khawaja Laeeq Ahmad,  
WHO Pakistan
120. Dr Iraneus Sindani, WHO  
Somalia

EURO
121. Dr Masoud Dara, Coordinator,  
TB/HIV and Hepatitis
122. Dr Martin van den Boom,  
EURO
123. Dr Jamshid Gadoev, WHO  
Uzbekistan
124. Dr Gayane Ghukasyan, WHO  
Armenia
125. Dr Ogtay Gozalov, WHO
126. Dr Javahir Suleymanova,  
WHO Azerbaijan
127. Dr Viatcheslav Grankov, WHO  
Belarus
128. Ms Nino Mamulashvili, WHO  
Georgia
SEARO
129. Dr Khurshid A. Hyder, Regional Adviser
130. Dr Sundari Mase, WHO India
131. Dr Muhammad Akhtar, WHO Indonesia
132. Dr Ikushi Onozaki, WHO Myanmar
133. Dr Mukta Sharma, WHO Thailand

WPRO
134. Dr Nobuyuki Nishikiori, Coordinator, TB and Leprosy Elimination
135. Dr Fabio Scano, WHO China
136. Dr Yanni Sun, WHO China
137. Dr Tauhidul Islam, MO/TB, WHO Papua New Guinea

WHO Headquarters Staff
138. Dr Ren Minghui, Assistant Director-General, HIV/AIDS, TB and Neglected Tropical Diseases Cluster (HTM)

Global TB Programme
139. Dr Mario Raviglione, Director

Policy, Strategy and Innovations Unit
140. Ms Diana Weil, Coordinator & STAG-TB Secretariat lead
141. Ms Hannah Monica Dias
142. Dr Mukund Uplekar
143. Ms Marzia Calvi
144. Mr Kristijan Marinkovic
145. Ms Chiara Moroni
146. Ms Jasmine Solangon (STAG-TB Secretariat)

TB/HIV and Community Engagement Unit

Laboratories Diagnostics and Drug Resistance Unit
153. Dr Karin Weyer, Coordinator
154. Dr Dennis Falzon
155. Dr Christopher Gilpin
156. Ms Licé Gonzalez-Angulo
157. Dr Ernesto Jaramillo
158. Dr Alexei Korobitsyn
159. Dr Fuad Mirzayev
160. Mr Wayne Van Gemert

Technical Support Coordination Unit
161. Dr Malgorzata Grzemska, Coordinator
162. Ms Natacha Barras
163. Ms Annemieke Brands
164. Ms Media Gegia
165. Dr Christian Günneberg
166. Ms Karina Halle
167. Ms Soleil Labelle
168. Dr Linh Nhat Nguyen
169. Dr Kefas Samson

TB Monitoring and Evaluation Unit
170. Dr Katherine Floyd, Coordinator
171. Dr Laura Anderson
172. Dr Anna Dean
173. Ms Ines Garcia Baena
174. Dr Philippe Glaziou
175. Dr Sayori Kobayashi
176. Dr Irwin Law
177. Dr Andrew Siroka
178. Dr Charalampos Sismanidis
179. Mr Hazim Timimi
180. Dr Matteo Zignol
Programme Management Unit
Unit
181. Dr Wieslaw Jakubowiak,
Programme Manager
182. Ms Melina Abrahan
183. Ms Yulia Bakonina
184. Ms Henrikka Weiss
185. Ms Tsira Gabadeva

Research for TB Elimination Team
186. Dr Christian Lienhardt, Team Leader
187. Dr Nebiat Gebreselassie
188. Dr Priya Shete

HIV/AIDS Department (HIV)
189. Dr Gottfried Hirnschall, Director
190. Dr Meg Doherty, Coordinator
191. Dr Satvinder Singh

Special Programme for Research and Training in Tropical Diseases (TDR)
192. Professor John Reeder, Director
193. Dr Dermot Maher, Coordinator,
RCS

DGO/Antimicrobial Resistance
194. Dr Marcus Sprenger, Director

DGO/Strategy, Policy and Information
195. Dr Christopher Dye

Global Coordination Mechanism Secretariat for NCDs
196. Mr Guy Fones